MXCT

MaxCyte Inc

1.43

Oct 20 • 3:59 PM ET +0.13 (10.00%)

1.35

Aftermarket • 7:32 PM ET -0.08 (-5.59%)

Healthcare Medical Devices USA Micro NASD

Peers: LAB TXG CTKB QSI TKNO RGEN DNA AZTA ABCL AVTR

| Held by: VTI VXF VHT BUSM BTEC

Scroll to Statements

Index	-
Market Cap	147.59M
Enterprise Value	59.15M
Income	-35.64M
Sales	31.05M
Book/sh	1.50
Cash/sh	1.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	91
IPO	Dec 05, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	4.75
P/B	0.96
P/C	1.40
P/FCF	-
EV/EBITDA	-
EV/Sales	1.90
Quick Ratio	11.47
Current Ratio	12.26
Debt/Eq	0.11
LT Debt/Eq	0.10
Option/Short	Yes / Yes

EPS (ttm)	-0.33
EPS next Y	-0.25
EPS next Q	-0.08
EPS this Y	34.78%
EPS next Y	6.91%
EPS next 5Y	17.03%
EPS past 3/5Y	-21.85% -19.78%
Sales past 3/5Y	-9.30% 4.76%
EPS Y/Y TTM	21.12%
Sales Y/Y TTM	-13.15%
EPS Q/Q	28.42%
Sales Q/Q	-14.53%
Earnings	Nov 10 AMC
EPS/Sales Surpr.	11.11% 11.75%

Insider Own	8.12%
Insider Trans	0.00%
Inst Own	64.74%
Inst Trans	-5.12%
ROA	-17.62%
ROE	-20.39%
ROIC	-20.42%
Gross Margin	66.17%
Oper. Margin	-103.98%
Profit Margin	-114.77%
SMA20	24.62%
SMA50	17.15%
SMA200	35.17%
Trades

Shs Outstand	106.13M
Shs Float	94.82M
Short Float	1.15%
Short Ratio	1.31
Short Interest	1.09M
52W High	1.80 -20.78%
52W Low	0.64 122.26%
Volatility	6.98% 5.41%
ATR (14)	0.08
RSI (14)	71.27
Beta	1.56
Rel Volume	1.67
Avg Volume	830.30K
Volume	1,390,115

Perf Week	48.29%
Perf Month	17.21%
Perf Quarter	25.44%
Perf Half Y	64.33%
Perf YTD	-7.74%
Perf Year	-18.29%
Perf 3Y	-54.17%
Perf 5Y	-86.80%
Perf 10Y	-
Recom	1.33
Target Price	4.11
Prev Close	1.30
Price	1.43
Change %	10.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-25	Downgrade	BTIG Research	Buy → Neutral
Aug-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-25	Initiated	Stephens	Overweight	$6
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Show Previous Ratings

Oct-14-26 08:05AM	MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance (GlobeNewswire) +29.63%
Sep-23-26 08:05AM	MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer (GlobeNewswire)
Sep-11-26 04:30PM	MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-19-26 08:05AM	MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies (GlobeNewswire) +9.45%
Aug-13-26 01:03AM	MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... (GuruFocus.com) +9.45%
09:50PM	Loading…
Aug-12-26 09:50PM	MaxCyte, Inc. Q2 2026 Earnings Call Summary (Moby)
04:05PM	MaxCyte Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-21-26 08:05AM	MaxCyte Announces Multi-Platform Technology License Partnership with Genentech to Advance Cell Therapy Development (GlobeNewswire) +5.13%
Jul-15-26 04:05PM	MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 (GlobeNewswire)
May-13-26 01:01AM	MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ... (GuruFocus.com) +24.06%
May-12-26 08:53PM	MaxCyte, Inc. Q1 2026 Earnings Call Summary (Moby)
04:05PM	MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance (GlobeNewswire)
Apr-29-26 04:05PM	MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 (GlobeNewswire) -6.78% +7.63%
Mar-31-26 04:05PM	MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.92%
Mar-25-26 08:30AM	MaxCyte, Inc. Q4 2025 Earnings Call Summary (Moby) -6.81%
11:01PM	Loading…
Mar-24-26 11:01PM	MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance (GlobeNewswire)
Mar-23-26 08:05AM	MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer (GlobeNewswire)
Feb-25-26 05:46AM	MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery (Insider Monkey)
Feb-24-26 08:05AM	MaxCyte unveils ExPERT DTx, a 96-well electroporation platform to accelerate discovery (GlobeNewswire) +5.01%
Feb-23-26 04:05PM	MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 (GlobeNewswire)
Jan-12-26 08:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Dec-01-25 09:00AM	Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO (Business Wire) -7.39%
Nov-13-25 12:01AM	MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges (GuruFocus.com)
Nov-12-25 04:08PM	MaxCyte Announces Planned CFO Transition in 2026 (GlobeNewswire)
04:05PM	MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance (GlobeNewswire)
Nov-10-25 05:25PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +5.44%
Nov-07-25 08:05AM	ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-05-25 08:05AM	MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance (GlobeNewswire)
Oct-08-25 08:05AM	MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire) +9.68%
08:05AM	Loading…
Oct-06-25 08:05AM	MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors (GlobeNewswire)
Sep-22-25 04:30PM	MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability (GlobeNewswire) +10.32%
Aug-11-25 07:45AM	MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio (Insider Monkey)
Aug-06-25 06:10PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -29.90%
04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 10:27AM	MaxCyte Inc (MXCT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
Jul-31-25 08:05AM	MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline (GlobeNewswire)
Jul-09-25 08:05AM	MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 01:00AM	PHC Announces Exclusive Distribution of MaxCyte® ExPERT Platform in Japan (Business Wire)
Jun-11-25 02:00AM	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies (GlobeNewswire)
May-13-25 10:51AM	MaxCyte, Inc. (MXCT): A Bull Case Theory (Insider Monkey)
May-08-25 03:27AM	MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ... (GuruFocus.com) -11.31%
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance (GlobeNewswire)
Apr-10-25 02:00AM	MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire) -7.51%
Apr-08-25 09:35AM	Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) (Zacks) -5.67%
Apr-07-25 09:35AM	Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround (Zacks)
Apr-04-25 12:00PM	MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know (Zacks) -5.77%
Mar-12-25 03:07AM	MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges (GuruFocus.com) -8.36%
Mar-11-25 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance (GlobeNewswire)
Feb-12-25 02:00AM	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs (GlobeNewswire)
Feb-07-25 02:00AM	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-30-25 02:00AM	MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments (GlobeNewswire)
Jan-15-25 12:00PM	All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy (Zacks)
Jan-13-25 03:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) +11.59%
Dec-23-24 02:00AM	MaxCyte Announces Retirement of Board Member Art Mandell (GlobeNewswire)
Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Mar 17 '26	Sale	0.81	10,142	8,266	151,669	Mar 19 04:05 PM

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

PresidentMr. Maher Masoud

Chief Financial OfficerMr. Parmeet Ahuja

Chief Operations OfficerMr. Jay Gelfman

Senior Vice President of Global SalesMs. Ana-Paula Martins Fernandes

Chief Corporate Development OfficerMr. Sidharth Kapileshwar

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MXCT

MaxCyte Inc

Upgrade your Finviz experience